NRIX

Nurix Therapeutics, Inc.

• Dow Jones·05/18 10:35

  Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG

• TipRanks·05/15 21:11

  Nurix Therapeutics Shareholders Back Directors and Governance Proposals

• PUBT·05/15 20:07

  Nurix Therapeutics shareholders ratify PwC as auditor for fiscal 2026

• TipRanks·05/15 19:15

  Gil Blum Reiterates Buy on Nurix, Maintains $26 Price Target on Advancing Degrader Pipeline

• TipRanks·05/15 15:16

  Stifel Nicolaus Keeps Their Buy Rating on Nurix Therapeutics (NRIX)

• TipRanks·05/15 12:30

  Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celcuity (CELC)

• TipRanks·05/13 12:18

  Nurix Therapeutics (NRIX) Receives a Buy from Oppenheimer

• PUBT·05/13 11:07

  Nurix CEO Sands to join RBC Global Healthcare Conference fireside chat

• Reuters·05/12 21:06

  BRIEF-Nurix Therapeutics Announces Bexobrutideg Oral Presentation

• PUBT·05/12 20:09

  Nurix to present updated Phase 1 data for BTK degrader bexobrutideg in CLL at EHA2026

• PUBT·05/05 23:54

  Nurix CFO Hans van Houte disposes of common shares worth $233,463.29

• PUBT·05/04 22:11

  Nurix Chief Legal Officer Christine Ring disposes 8,148 shares worth $138,205

• PUBT·05/01 21:51

  Nurix Chief Legal Officer Christine Ring sells 5,394 shares for $90,435

• Dow Jones·04/27 11:59

  Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

• Benzinga·04/27 11:48

  HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target